glp-1 agonist and heart failure The cardiovascular effects of receptor agonists beyond obesity type 2 diabetes: An anti-atherosclerotic action GLP-1 receptor agonists and myocardial

Lower prices will also make compounded GLP-1 drugs less attractive to patients

This highlights the need to balance the benefits and disadvantages of such use and to regularly reassess the need for continued proton pump inhibitor treatment. The research was published in The British Medical Journal (BMJ)

Medicare is not allowed to cover weight-loss drugs under current law and Medicaid coverage varies by state

Implications of generic GLP-1 access The launch of a generic Saxenda could make weight-loss treatment more affordable

Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data

Immune-modulating peptides may influence angiogenesis, fibrosis, or tumor biology, requiring indication-specific risk assessment